Evidence map›Paper›PMID 25398241›Full record

ArticleThe Journal of pharmacology and experimental therapeutics2015

Δ9-tetrahydrocannabinol and endocannabinoid degradative enzyme inhibitors attenuate intracranial self-stimulation in mice.

Jason M Wiebelhaus, Travis W Grim, Robert A Owens, Matthew F Lazenka, Laura J Sim-Selley, Rehab A Abdullah, Micah J Niphakis, Robert E Vann, Benjamin F Cravatt, Jenny L Wiley and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of pharmacology and experimental therapeutics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
3.5field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 36 citations in OpenAlex.

  1. FAAH and MAGL inhibition: Evolving approaches to treating substance use disorders.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Receptor mechanisms underlying the CNS effects of cannabinoids: CBAdvances in pharmacology (San Diego, Calif.) · 2022
    Article
  9. Article
  10. Article
  11. Dissecting the role of CBEuropean neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology · 2021
    Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Cannabinoid CBBritish journal of pharmacology · 2019
    Article
  17. Brain activity of anandamide: a rewarding bliss?Acta pharmacologica Sinica · 2019
    Review
  18. Article
  19. Article
  20. Cannabinoid disruption of learning mechanisms involved in reward processing.Learning & memory (Cold Spring Harbor, N.Y.) · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Jason M WiebelhausDepartment of Pharmacology and Toxicology, Virginia Commonwealth University School of Medicine, Richmond, Virginia (J.M.W., T.W.G., R.A.O., M.F.L., L.J.S.-S., R.A.A., R.E.V., S.S.N., A.H.L.); Skaggs Institute for Chemical Biology and Department of Chemical Physiology, Scripps Research Institute, La Jolla, California (M.J.N., B.F.C.); and RTI International, Research Triangle Park, North Carolina (J.L.W.) wiebelhausjm@vcu.edu.
Travis W GrimDepartment of Pharmacology and Toxicology, Virginia Commonwealth University School of Medicine, Richmond, Virginia (J.M.W., T.W.G., R.A.O., M.F.L., L.J.S.-S., R.A.A., R.E.V., S.S.N., A.H.L.); Skaggs Institute for Chemical Biology and Department of Chemical Physiology, Scripps Research Institute, La Jolla, California (M.J.N., B.F.C.); and RTI International, Research Triangle Park, North Carolina (J.L.W.).
Robert A OwensDepartment of Pharmacology and Toxicology, Virginia Commonwealth University School of Medicine, Richmond, Virginia (J.M.W., T.W.G., R.A.O., M.F.L., L.J.S.-S., R.A.A., R.E.V., S.S.N., A.H.L.); Skaggs Institute for Chemical Biology and Department of Chemical Physiology, Scripps Research Institute, La Jolla, California (M.J.N., B.F.C.); and RTI International, Research Triangle Park, North Carolina (J.L.W.).
Matthew F LazenkaDepartment of Pharmacology and Toxicology, Virginia Commonwealth University School of Medicine, Richmond, Virginia (J.M.W., T.W.G., R.A.O., M.F.L., L.J.S.-S., R.A.A., R.E.V., S.S.N., A.H.L.); Skaggs Institute for Chemical Biology and Department of Chemical Physiology, Scripps Research Institute, La Jolla, California (M.J.N., B.F.C.); and RTI International, Research Triangle Park, North Carolina (J.L.W.).
Laura J Sim-SelleyDepartment of Pharmacology and Toxicology, Virginia Commonwealth University School of Medicine, Richmond, Virginia (J.M.W., T.W.G., R.A.O., M.F.L., L.J.S.-S., R.A.A., R.E.V., S.S.N., A.H.L.); Skaggs Institute for Chemical Biology and Department of Chemical Physiology, Scripps Research Institute, La Jolla, California (M.J.N., B.F.C.); and RTI International, Research Triangle Park, North Carolina (J.L.W.).
Rehab A AbdullahDepartment of Pharmacology and Toxicology, Virginia Commonwealth University School of Medicine, Richmond, Virginia (J.M.W., T.W.G., R.A.O., M.F.L., L.J.S.-S., R.A.A., R.E.V., S.S.N., A.H.L.); Skaggs Institute for Chemical Biology and Department of Chemical Physiology, Scripps Research Institute, La Jolla, California (M.J.N., B.F.C.); and RTI International, Research Triangle Park, North Carolina (J.L.W.).
Micah J NiphakisDepartment of Pharmacology and Toxicology, Virginia Commonwealth University School of Medicine, Richmond, Virginia (J.M.W., T.W.G., R.A.O., M.F.L., L.J.S.-S., R.A.A., R.E.V., S.S.N., A.H.L.); Skaggs Institute for Chemical Biology and Department of Chemical Physiology, Scripps Research Institute, La Jolla, California (M.J.N., B.F.C.); and RTI International, Research Triangle Park, North Carolina (J.L.W.).
Robert E VannDepartment of Pharmacology and Toxicology, Virginia Commonwealth University School of Medicine, Richmond, Virginia (J.M.W., T.W.G., R.A.O., M.F.L., L.J.S.-S., R.A.A., R.E.V., S.S.N., A.H.L.); Skaggs Institute for Chemical Biology and Department of Chemical Physiology, Scripps Research Institute, La Jolla, California (M.J.N., B.F.C.); and RTI International, Research Triangle Park, North Carolina (J.L.W.).
Benjamin F CravattDepartment of Pharmacology and Toxicology, Virginia Commonwealth University School of Medicine, Richmond, Virginia (J.M.W., T.W.G., R.A.O., M.F.L., L.J.S.-S., R.A.A., R.E.V., S.S.N., A.H.L.); Skaggs Institute for Chemical Biology and Department of Chemical Physiology, Scripps Research Institute, La Jolla, California (M.J.N., B.F.C.); and RTI International, Research Triangle Park, North Carolina (J.L.W.).
Jenny L WileyDepartment of Pharmacology and Toxicology, Virginia Commonwealth University School of Medicine, Richmond, Virginia (J.M.W., T.W.G., R.A.O., M.F.L., L.J.S.-S., R.A.A., R.E.V., S.S.N., A.H.L.); Skaggs Institute for Chemical Biology and Department of Chemical Physiology, Scripps Research Institute, La Jolla, California (M.J.N., B.F.C.); and RTI International, Research Triangle Park, North Carolina (J.L.W.).
S Stevens NegusDepartment of Pharmacology and Toxicology, Virginia Commonwealth University School of Medicine, Richmond, Virginia (J.M.W., T.W.G., R.A.O., M.F.L., L.J.S.-S., R.A.A., R.E.V., S.S.N., A.H.L.); Skaggs Institute for Chemical Biology and Department of Chemical Physiology, Scripps Research Institute, La Jolla, California (M.J.N., B.F.C.); and RTI International, Research Triangle Park, North Carolina (J.L.W.).
Aron H LichtmanDepartment of Pharmacology and Toxicology, Virginia Commonwealth University School of Medicine, Richmond, Virginia (J.M.W., T.W.G., R.A.O., M.F.L., L.J.S.-S., R.A.A., R.E.V., S.S.N., A.H.L.); Skaggs Institute for Chemical Biology and Department of Chemical Physiology, Scripps Research Institute, La Jolla, California (M.J.N., B.F.C.); and RTI International, Research Triangle Park, North Carolina (J.L.W.).
Virginia Commonwealth University · USRTI International · USScripps Research Institute · US

Funding

TRAINING IN THE PHARMACOLOGY OF ABUSED DRUGST32DA007027 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI William L. Dewey · 1985 to 2026
$14.7M
VCU Center for Drug Addiction ResearchP30DA033934 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI ARON H LICHTMAN · 2014 to 2026
$13.8M
SYNTHESIS OF SR141716A AND ANANDAMIDE ANALOGSP01DA009789 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI LICHTMAN, ARON H · 1995 to 2013
$11.6M
STRUCTURAL STUDIES OF FAAHP01DA017259 · NIDA · SCRIPPS RESEARCH INSTITUTE, THE · PI CRAVATT, BENJAMIN F · 2004 to 2013
$10.6M
Virginia Commonwealth University Initiative for Maximizing Student DevelopmentR25GM090084 · NIGMS · VIRGINIA COMMONWEALTH UNIVERSITY · PI AKBARALI, HAMID I, LLOYD, JOYCE A. · 2010 to 2022
$5.2M
Endocannabinoid modulation of pain-depressed behaviorR01DA030404 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI NEGUS, SIDNEY S, SIM-SELLEY, LAURA J · 2011 to 2020
$3.7M
Monoacylglycerol Lipase Inhibitors for Treating Opioid Use Disorders (RO)R01DA032933 · NIDA · SCRIPPS RESEARCH INSTITUTE, THE · PI CRAVATT, BENJAMIN F, LICHTMAN, ARON H · 2012 to 2014
$1.5M
Endocannabinoid DiscriminationR01DA026449 · NIDA · RESEARCH TRIANGLE INSTITUTE · PI WILEY, JENNY L. · 2010 to 2014
$1.5M
Examination of endocannabinoid elevation and extinction learningF31DA030869 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI WIEBELHAUS, JASON MICHAEL · 2011 to 2013
$86k
NIDA NIH HHS F31 DA030869NIDA NIH HHS F31-DA030869NIDA NIH HHS P01 DA009789NIDA NIH HHS P01-DA009789NIDA NIH HHS P01 DA017259NIDA NIH HHS P01-DA017259NIDA NIH HHS P30 DA033934NIDA NIH HHS P30-DA033934NIDA NIH HHS R01 DA026449NIDA NIH HHS R01-DA026449NIDA NIH HHS R01 DA030404NIDA NIH HHS R01-DA030404NIDA NIH HHS R01 DA032933NIDA NIH HHS R01-DA032933NIDA NIH HHS T32 DA007027NIDA NIH HHS T32-DA007027NIGMS NIH HHS R25 GM090084
6 · The paper itself

Abstract

A growing body of evidence implicates endogenous cannabinoids as modulators of the mesolimbic dopamine system and motivated behavior. Paradoxically, the reinforcing effects of Δ(9)-tetrahydrocannabinol (THC), the primary psychoactive constituent of cannabis, have been difficult to detect in preclinical rodent models. In this study, we investigated the impact of THC and inhibitors of the endocannabinoid hydrolytic enzymes fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL) on operant responding for electrical stimulation of the medial forebrain bundle [intracranial self-stimulation (ICSS)], which is known to activate the mesolimbic dopamine system. These drugs were also tested in assays of operant responding for food reinforcement and spontaneous locomotor activity. THC and the MAGL inhibitor JZL184 (4-[bis(1,3-benzodioxol-5-yl)hydroxymethyl]-1-piperidinecarboxylic acid 4-nitrophenyl ester) attenuated operant responding for ICSS and food, and also reduced spontaneous locomotor activity. In contrast, the FAAH inhibitor PF-3845 (N-3-pyridinyl-4-[[3-[[5-(trifluoromethyl)-2-pyridinyl]oxy]phenyl]methyl]-1-piperidinecarboxamide) was largely without effect in these assays. Consistent with previous studies showing that combined inhibition of FAAH and MAGL produces a substantially greater cannabimimetic profile than single enzyme inhibition, the dual FAAH-MAGL inhibitor SA-57 (4-[2-(4-chlorophenyl)ethyl]-1-piperidinecarboxylic acid 2-(methylamino)-2-oxoethyl ester) produced a similar magnitude of ICSS depression as that produced by THC. ICSS attenuation by JZL184 was associated with increased brain levels of 2-arachidonoylglycerol (2-AG), whereas peak effects of SA-57 were associated with increased levels of both N-arachidonoylethanolamine (anandamide) and 2-AG. The cannabinoid receptor type 1 receptor antagonist rimonabant, but not the cannabinoid receptor type 2 receptor antagonist SR144528, blocked the attenuating effects of THC, JZL184, and SA-57 on ICSS. Thus, THC, MAGL inhibition, and dual FAAH-MAGL inhibition not only reduce ICSS, but also decrease other reinforced and nonreinforced behaviors.

Indexed as

Reinforcement, PsychologySelf StimulationAmidohydrolasesAnimalsBehavior, AnimalBenzodioxolesBiphenyl CompoundsConditioning, OperantDose-Response Relationship, DrugDronabinolElectric StimulationEndocannabinoidsEnzyme InhibitorsFatty Acid Amide HydrolasesMaleMedial Forebrain BundleAmidohydrolasesBenzodioxolesBiphenyl CompoundsDronabinolEndocannabinoidsEnzyme InhibitorsFatty Acid Amide HydrolasesJZL 184Monoacylglycerol LipasesN,N'-dimethyl-4,4'-(biphenyl-2,1-ethenediyl)dipyridiniumPiperidinesPyridinium Compounds

Identifiers

PMID25398241
PMCPMC4293433
OpenAlexW2066487397

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.